Capreomycin
Based on 5 publication(s) in Google Scholar
Capreomycin is a macrocyclic peptide antibiotic. Capreomycin can be used for anti-multidrug-resistant-tuberculosis research. Capreomycin can inhibit phenylalanine synthesis in in mycobacterial ribosomes translation
For research use only. We do not sell to patients.
- CAS No.: 11003-38-6
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Capreomycin
MoreAll Antibiotic Isoforms
More
Biological Activity
|
Aminoglycoside |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male guinea pigs [836 ± 162.3 g; infected via the respiratory route with nebulized suspensions 2 × 105 CFU/mL of Mycobacterium tuberculosis (strain H37Rv)][2]
-
Dosage:1.4, 7.2, and 14.5 mg/kg for inhale; 20 mg/kg for i.m.
-
Administration:Inhaling or i.m.; 4 weeks
-
Result:Significantly decreased the wet lung weight at 14.5 mg/kg, and smaller than receiving 1.4 mg/kg group and controls.
Significantly lowered bacterial burden in the lungs (3.52 ± 0.20 CFU/mL; P < 0.05) at 14.5 mg/kg than controls (4.58 ± 0.20 CFU/mL) and at 1.4 and 7.2 mg/kg (4.02 ± 0.32 and 4.01 ± 0.29 CFU/mL, respectively).
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 11003-38-6
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
EBioMedicine
Diverse impacts of different rpoB mutations on the anti-tuberculosis efficacy of capreomycin. [Abstract]2025 May 30:117:105776. PMID: 40449326 -
mLife
Identification of a phenyl ester covalent inhibitor of caseinolytic protease and analysis of the ClpP1P2 inhibition in mycobacteria. [Abstract]2025 Apr 15;4(2):155-168. PMID: 40313980 -
ACS Chem Biol
Investigate Natural Product Indolmycin and the Synthetically Improved Analogue Toward Antimycobacterial Agents. [Abstract]2022 Jan 21;17(1):39-53. PMID: 34908399 -
Tuberculosis
2024 Jul 26:148:102551. PMID: 39084000 -
Purity & Documentation
References
[1]. Maus CE, et al. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2005 Feb;49(2):571-7. [Content Brief]
[2]. Garcia-Contreras L, et al. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother. 2007 Aug;51(8):2830-6. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz